Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Amortization of Deferred Charges: 2019-2020

Historic Amortization of Deferred Charges for Protagonist Therapeutics (PTGX) over the last 2 years, with Dec 2020 value amounting to $1.8 million.

  • Protagonist Therapeutics' Amortization of Deferred Charges rose 10.59% to $491,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.8 million, marking a year-over-year increase of 2.59%. This contributed to the annual value of $1.8 million for FY2020, which is 0.95% down from last year.
  • Protagonist Therapeutics' Amortization of Deferred Charges amounted to $1.8 million in FY2020, which was down 0.95% from $1.8 million recorded in FY2019.
  • Over the past 5 years, Protagonist Therapeutics' Amortization of Deferred Charges peaked at $1.8 million during FY2019, and registered a low of $1.8 million during FY2020.
  • Moreover, its 2-year median value for Amortization of Deferred Charges was $1.8 million (2019), whereas its average is $1.8 million.
  • Data for Protagonist Therapeutics' Amortization of Deferred Charges shows a maximum YoY dropped of 0.95% (in 2020) over the last 5 years.
  • Over the past 2 years, Protagonist Therapeutics' Amortization of Deferred Charges (Yearly) stood at $1.8 million in 2019, then decreased by 0.95% to $1.8 million in 2020.